[go: up one dir, main page]

AU2010902655A0 - Cancer Cell Regulation - Google Patents

Cancer Cell Regulation

Info

Publication number
AU2010902655A0
AU2010902655A0 AU2010902655A AU2010902655A AU2010902655A0 AU 2010902655 A0 AU2010902655 A0 AU 2010902655A0 AU 2010902655 A AU2010902655 A AU 2010902655A AU 2010902655 A AU2010902655 A AU 2010902655A AU 2010902655 A0 AU2010902655 A0 AU 2010902655A0
Authority
AU
Australia
Prior art keywords
cancer cell
cell regulation
regulation
cancer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010902655A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Propanc Pty Ltd
University of Bath
Original Assignee
Propanc Pty Ltd
University of Bath
Filing date
Publication date
Application filed by Propanc Pty Ltd, University of Bath filed Critical Propanc Pty Ltd
Publication of AU2010902655A0 publication Critical patent/AU2010902655A0/en
Priority to CA2814958A priority Critical patent/CA2814958C/en
Priority to TR2018/15315T priority patent/TR201815315T4/en
Priority to BR112012009521-8A priority patent/BR112012009521B1/en
Priority to SG10201406651PA priority patent/SG10201406651PA/en
Priority to CN201710885368.4A priority patent/CN107625957B/en
Priority to EP16174383.6A priority patent/EP3095458B1/en
Priority to EP10824316A priority patent/EP2490711A4/en
Priority to PT16174383T priority patent/PT3095458T/en
Priority to RU2012120785/15A priority patent/RU2012120785A/en
Priority to DK16174383.6T priority patent/DK3095458T3/en
Priority to MX2012004610A priority patent/MX355971B/en
Priority to US13/502,917 priority patent/US9636359B2/en
Priority to JP2012534496A priority patent/JP5871805B2/en
Priority to CN201080054056.5A priority patent/CN102639145B/en
Priority to PE2012000530A priority patent/PE20121709A1/en
Priority to AU2010310887A priority patent/AU2010310887B9/en
Priority to MX2017009455A priority patent/MX387621B/en
Priority to PCT/AU2010/001403 priority patent/WO2011047434A1/en
Priority to ES16174383.6T priority patent/ES2692377T3/en
Priority to NZ599996A priority patent/NZ599996A/en
Priority to KR1020127012943A priority patent/KR101936439B1/en
Priority to IL219216A priority patent/IL219216A/en
Priority to CL2012001019A priority patent/CL2012001019A1/en
Priority to ZA2012/03689A priority patent/ZA201203689B/en
Priority to US15/462,655 priority patent/US10350239B2/en
Priority to HK18108670.0A priority patent/HK1249017B/en
Priority to US16/428,581 priority patent/US20190388463A1/en
Priority to US17/862,120 priority patent/US20230137573A1/en
Abandoned legal-status Critical Current

Links

AU2010902655A 2009-10-22 2010-06-17 Cancer Cell Regulation Abandoned AU2010902655A0 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
KR1020127012943A KR101936439B1 (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
JP2012534496A JP5871805B2 (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen.
PE2012000530A PE20121709A1 (en) 2009-10-22 2010-10-22 A PHARMACEUTICAL COMPOSITION TO TREAT CANCER INCLUDING TRYPSINOGEN AND / OR CHEMOTRIPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VAINILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCING AGENT
BR112012009521-8A BR112012009521B1 (en) 2009-10-22 2010-10-22 PHARMACEUTICAL COMPOSITION AND USE OF CHYMOTRIPSINOGEN AND TRIPSINOGEN
SG10201406651PA SG10201406651PA (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent
CN201710885368.4A CN107625957B (en) 2009-10-22 2010-10-22 Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
EP16174383.6A EP3095458B1 (en) 2009-10-22 2010-10-22 Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
EP10824316A EP2490711A4 (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
PT16174383T PT3095458T (en) 2009-10-22 2010-10-22 Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
RU2012120785/15A RU2012120785A (en) 2009-10-22 2010-10-22 PHARMACEUTICAL COMPOSITIONS
DK16174383.6T DK3095458T3 (en) 2009-10-22 2010-10-22 PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT INCLUDING TRYPSINOGEN AND CHYMOTRYPSINOGEN
MX2012004610A MX355971B (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent.
US13/502,917 US9636359B2 (en) 2009-10-22 2010-10-22 Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
CA2814958A CA2814958C (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
CN201080054056.5A CN102639145B (en) 2009-10-22 2010-10-22 Pharmaceutical composition for the treatment of cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from selenium compounds, vanilloid compounds and cytoplasmic glycolysis reducing agents
MX2017009455A MX387621B (en) 2009-10-22 2010-10-22 A PHARMECTIVE COMPOSITION FOR TREATING CANCER THAT COMPRISES TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCING AGENT.
NZ599996A NZ599996A (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
AU2010310887A AU2010310887B9 (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
PCT/AU2010/001403 WO2011047434A1 (en) 2009-10-22 2010-10-22 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
ES16174383.6T ES2692377T3 (en) 2009-10-22 2010-10-22 Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
TR2018/15315T TR201815315T4 (en) 2009-10-22 2010-10-22 Pharmaceutical composition comprising trypsinogen and chymotrypsinogen for the treatment of cancer.
IL219216A IL219216A (en) 2009-10-22 2012-04-16 Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
CL2012001019A CL2012001019A1 (en) 2009-10-22 2012-04-20 Pharmaceutical composition comprising a protease proenzyme selected from at least trypsinogen and chymotrypsinogen and an active agent selected from at least one selenium compound, a vanilloid compound, a cytoplasmic glycolysis reducing agent and optionally a glycosidohydrolase; and use to treat cancer.
ZA2012/03689A ZA201203689B (en) 2009-10-22 2012-05-21 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a sytoplasmic glycolysis reduction agent
US15/462,655 US10350239B2 (en) 2009-10-22 2017-03-17 Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent
HK18108670.0A HK1249017B (en) 2009-10-22 2018-07-04 A pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
US16/428,581 US20190388463A1 (en) 2009-10-22 2019-05-31 Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent
US17/862,120 US20230137573A1 (en) 2009-10-22 2022-07-11 Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent

Publications (1)

Publication Number Publication Date
AU2010902655A0 true AU2010902655A0 (en) 2010-07-01

Family

ID=

Similar Documents

Publication Publication Date Title
IL255309A0 (en) Reprogramming cancer cells
GB201017421D0 (en) Cell
EP2506312A4 (en) Solar cell
AU2010100385A4 (en) Eldeap
EP2541615A4 (en) Solar cell
AU2010902655A0 (en) Cancer Cell Regulation
AU2010101066A4 (en) Tropidry
EP2569412A4 (en) Biovessels
AU2009902760A0 (en) Cancer Cell Regulation
AU2013204145B2 (en) Pure erlotinib
AU2010100344A4 (en) Icbd
AU2010101200A4 (en) Ileo-alert
AU2010100523A4 (en) Brakebuddy
AU2010100625A4 (en) TreeCups
AU2010100716A4 (en) Whatsthatbillboard
AU2010901021A0 (en) Solar Cells
AU2010901020A0 (en) Batteries
GB201020580D0 (en) Cells
GB201019304D0 (en) Cells
EP2598166A4 (en) Mhc-less cells
AU2010904355A0 (en) Cell Module
AU2010902305A0 (en) Electrolysis cell improvement
AU2010902339A0 (en) Not Given
AU2010900620A0 (en) Not Given
AU2010905253A0 (en) Not given